Acute Myeloid Leukemia: Focus on Novel Therapeutic Strategies
Acute myeloid leukemia (AML) is a heterogeneous disease with variable clinical outcomes. Cytogenetic analysis reveals which patients may have favorable risk disease, but 5-year survival in this category is only approximately 60%, with intermediate and poor risk groups faring far worse. Advances in o...
| Main Authors: | , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Libertas Academica
2012
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3362331/ |